Johnson & Johnson (J&J) has received approval for Darzalex, a multiple myeloma drug that patients can inject themselves. This is the first approval of an injectable cancer drug that is intended for self-administration. Analysts believe that this change could improve the availability of the drug for patients. Self-administration of Darzalex is expected to contribute to its wider use in the treatment of multiple myeloma.